Eton Pharmaceuticals, Inc.

Second quarter 2026 revenue was $37.6 million, up 99% from $18.9 million in the second quarter of 2025. Gross profit was $25.4 million, up 113% from $11.9 million, and adjusted gross profit was $27.4 million with an adjusted gross margin of 73% versus 75% last year. Adjusted EBITDA was $16.2 million, or 43% of revenue, versus $3.1 million to $3.6 million in the prior-year quarter as stated on the call; net income was $11.6 million, or $0.35 per diluted share, versus a net loss of $2.6 million, or $0.10 per share. Full-year 2026 revenue guidance was raised to exceed $145 million from more than $120 million, adjusted EBITDA margin is expected to exceed 35%, full-year adjusted gross margin is expected to exceed 70%, and R&D spend is expected to be between $10 million and $14 million, including a $3 million ASN-001 upfront licensing payment. Management said ASN-001’s bioavailability study should cost about $4 million over the next 12 months. Cash ended at $26.8 million after a $3 million debt prepayment, and the company expects cash from operations to grow in the second half while prioritizing product acquisitions and repayment of its remaining credit facility over the next 6-12 months.

Sean Brynjelsen framed the quarter as evidence that Eton’s model is scaling, citing record revenue, margin expansion, and operating leverage. He emphasized that HEMANGEOL is performing ahead of expectations, ASN-001 could become the company’s largest product, and the company is building repeatable franchises by entering niche therapeutic areas and then expanding them. His tone was upbeat and confident, repeatedly pointing to long-term margin potential above 50% and a path to $500 million in annual revenue by 2030.

Judy Matthews focused on the financial acceleration: revenue of $37.6 million, gross profit of $25.4 million, adjusted gross margin of 73%, adjusted EBITDA of $16.2 million, and diluted EPS of $0.43 on a non-GAAP basis. She highlighted that higher Increlex sales outside the U.S. pressured adjusted gross margin because they carry negative gross margin, but still said full-year adjusted gross margin should exceed 70%. She also noted $26.8 million in cash at quarter end, a $3 million prepayment on debt, and the plan to use cash for accretive acquisitions while accelerating debt repayment.

Analysts focused on HEMANGEOL pricing, patient retention, and how much the relaunch contributed to the beat; management said net pricing still appears to be around $8,000-$10,000 per full course and that they believe they have now converted essentially all prior patients to the new model. Questions also centered on ASN-001’s FDA path and synergy with HEMANGEOL; management said the remaining study is straightforward, is the only study needed before filing, and could support a filing around the middle of 2027. On IMPAVIDO, management said commercialization had previously been underdeveloped, with no field force and limited access support, and described a concentrated opportunity of around 300 sales targets with Eton Cares and $0 copay support. Analysts also pressed on sales force expansion and HEMANGEOL’s long-term economics; management said no sales force expansion is planned and that HEMANGEOL still has runway even as ASN-001 complements it.